EUCTR2006-002515-27-ES进行中（未招募）不适用
Estudio doble ciego, aleatorizado, controlado con placebo, multicéntrico para valorar la eficacia y seguridad de zonisamida como tratamiento adyuvante en crisis epilépticas parciales en Pediatría. - CATZ
Eisai Ltd0 个研究点目标入组 266 人开始时间: 2008年6月12日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 266
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is male or female aged 6–17 years inclusive.
- •2. Parent/guardian is willing to sign an approved informed consent form, and
- •accompany the subject on all study visits.
- •3. Subject is willing to give informed (written or verbal) assent and if appropriate
- •written informed consent.
- •4. Subject has a clinical diagnosis of epilepsy with partial-onset seizures with or
- •without secondary generalized seizures according to the International League
- •Against Epilepsy’s Classification of Epileptic Seizures (1981).
- •5. Diagnosis should have been established by clinical history, electroencephalogram
- •(EEG) and computed tomography/ magnetic resonance imaging (CT/MRI) of the
- •brain consistent with localisation related epilepsy.
- •6. Subject has = four (simple or complex) partial seizures (with or without secondary
- •generalisation) per month over the eight week Screening Period with at least one
- •seizure in each four week period and with no 21 day period being seizure free.
- •7. Subject is taking a stable regimen of one or two other AEDs for at least one month
- •prior to Visit 1 (start of the Screening Period).
- •NOTE: If using a vagal nerve stimulator (VNS), it must have been implanted for
- •at least five months and stimulator parameters must remain unchanged for at least
- •one month prior to Visit 1 (start of the Screening Period), and throughout the
- •entire study period. VNS will be considered as one AED for the purposes of this
- •8. Subject is in general good health as determined by medical history, physical exam
- •and screening laboratory results.
- •9. Parent/guardian is willing and able to complete a seizure diary for the duration of
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject of body weight < 20 kg at the Screening Visit.
- •2. Subject is unable to swallow capsules.
- •3. Subject has progressive neurological disease (determined by diagnosis or a preexisting brain image such as a CT scan or MRI).
- •4. Subject has a history of idiopathic generalised epilepsy as defined by the
- •International League Against Epilepsy (ILAE).
- •5. Subjects with Lennox-Gastaut syndrome, absence, myoclonic, clonic and/or tonic
- •(other than secondary generalised) and atonic seizures.
- •6. Subject has psychogenic seizures.
- •7. Subject has a history of status epilepticus within a year of the Screening Visit
- •whilst taking AEDs.
- •8. Subject has seizures that only occur in clustered patterns, or has seizures that are
- •too close together to count accurately.
- •9. Subject has a history of renal calculi or renal insufficiency (creatinine levels >194
- •µmol/l (1.5mg1/dl).
- •10. Subject had a predisposing condition that might interfere with absorption,
- •distribution, or excretion of zonisamide.
- •11. Subject has a history of psychiatric illness.
- •12. Subject has a history of suicide attempt.
- •13. Female subject who is pregnant or lactating.
- •14. Subject has a history of demonstrated non-compliance with treatment or, the
- •subject, parent or legal guardian can be reasonably expected not to be compliant
- •with study procedures or to complete the study.
- •15. Female subject of 10 years or greater or of child bearing potential (i.e. started
- •menses) and is not taking or prepared to take a medically acceptable form of
- •contraception (i.e. oral contraceptive pill, surgical sterilisation, an implant or an
- •injected form of contraception or intrauterine device), or who is not prepared to
- •abstain from sexual activity for the duration of the study and one month after last
- •administration of study medication.
- •NOTE: Should a female subject become of childbearing potential during the study,
- •they must be reconsented, in order to give consent to undergo pregnancy testing
- •and either confirm abstinence or receive medically appropriate form of
- •contraception.
- •16. Subject has clinically significant abnormal laboratory values at the Screening Visit
- •17. Subject has received previous treatment with zonisamide.
- •18. Subject is treated with a ketogenic diet or is likely to have surgery for epilepsy in
- •the trial period.
- •19. Subject requires frequent rescue benzodiazepines (one or more times a month).
- •20. Concomitant use of felbamate or use of felbamate within 2 months prior to Visit 1.
- •21. Subject has elevations of liver enzymes, alanine aminotransferase (ALT), and
- •aspartate aminotransferase (AST) > 2 times the upper limit of normal (ULN).
- •22. Subject has evidence of significant active and unstable haematological disease; i.e.
- •white blood cell (WBC) count < 2500/µL or an absolute neutrophil count <
- •23. Subject with clinically significant active hepatic disease, cardiovascular,
- •metabolic, respiratory, renal, endocrinological, any other clinically significant
- •organic diseases and gastrointestinal diseases within 30 days prior to the
- •Screening Visit.
- •24. Subjects with known or suspected history of alcoholism or drug abuse within the
- •previous two years, or a positive finding on urinary drug screening of any drugs
- •other than prescribed medications.
- •25. Subjects with any other condition that would make them, in the opinion of the
- 另有 3 项未显示
研究者
相似试验
进行中（未招募）
不适用
Estudio doble ciego, aleatorizado, controlado con placebo, de búsqueda de dosis para evaluar la eficacia y la seguridad de PF-00547659 en sujetos con enfermedad de Crohn que no responden adecuadamente al tratamiento anti-TNF (OPERA)A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN SUBJECTS WITH CROHN?S DISEASE WHO ARE ANTI-TNF INADEQUATE RESPONDERS (OPERA) - OPERAEnfermedad de Crohn Crohn's DiseaseMedDRA version: 13.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-023437-30-ESPFIZER S240
进行中（未招募）
不适用
Estudio doble ciego, aleatorizado, controlado con placebo, multicéntrico, de grupos paralelos para evaluar la eficacia de Lymphomyosot en la reducción de la incidencia de amigdalectomía en pacientes con amigdalitis recurrente- Double blind study, randomized, controlled with placebo, multicentric, parallel groups to assess the eficacy of Lymphomyosot in the reduction of the incidence of tonsillectomy in patients with chronic tonsillitis.AMIGDALITIS CRÓNICAMedDRA version: 9Level: LLTClassification code 10009152Term: Chronic tonsillitisEUCTR2009-015624-28-ESHéctor Guiral Torner
进行中（未招募）
1 期
Estudio doble ciego, aleatorizado, controlado con placebo, de grupos paralelos para evaluar los efectos de un tratamiento de 4 semanas con dosis orales de MEN15596 en el síndrome de colon irritable.Double blind, randomized, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of MEN15596 in irritable bowel syndrome. - Not applicableIrritable Bowel Syndrome.MedDRA version: 9.1Level: LLTClassification code 10023003Term: Irritable bowel syndromeEUCTR2008-000214-71-ESaboratorios Menarini S.A. (Menarini Group)554
进行中（未招募）
1 期
Estudio doble ciego, aleatorizado, controlado con placebo y alprazolam, de diseño cruzado con tres periodos y bloques incompletos, para comparar mediante Resonancia Magnética Funcional, las posibles propiedades ansiolíticas de GW876008 y GSK561679, tras la administración de una dosis única, en sujetos con trastorno de fobia social.EUCTR2006-004212-48-ESGlaxoSmithKline S.A.
进行中（未招募）
不适用
Estudio doble ciego, aleatorizado, controlado con placebo de dosis escaladas de deferoxamina intravenosa en pacientes con ictus isquémico agudo tratado con activador tisular del plasminógeno.Double-blind, randomized, placebo controlled, dose-finding phase II clinical trial of intravenous deferoxamine in patients with acute ischemic stroke treated with tissue plasminogen activator. - tandem-1EUCTR2007-006731-31-ESFundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol